Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Emicizumab vs No Prophylaxis in Hemophilia A Without Inhibitors (Phase III)
2016-000072-17Phase 3Unknown
- Sponsor
- Roche
- Start
- Mar 2016
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of emicizumab in hemophilia A (2 arms), sponsored by Roche. Primary endpoint: Number of bleeds over time (treated bleeds). Status: unknown.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2016-000072-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000072-17.